Cronos Group Posts Record Q2 Revenue, Swings to Profit, and Flags New Israeli Anti-Dumping Probe
CRON sits 54% above its 52-week low of $2.
Summary
Cronos Group posted record Q2 2026 results with revenue up 58%, a swing to profitability, and strong cash generation, while also disclosing a new Israeli anti-dumping probe that could threaten its top growth market.
Key Events · Earnings and Guidance · CRON
-
Record Q2 Revenue and Profitability
Net revenue rose 58% YoY to $53.0M (51% organic constant-currency), gross profit nearly doubled to $28.5M (54% margin), and net income swung to $35.7M from a $38.5M loss a year ago.
-
Adjusted EBITDA Surge
Adjusted EBITDA reached $13.1M, up from $1.7M in Q2 2025, driven by higher sales volumes and a favorable product mix shift toward Israel and Germany, where no excise taxes apply.
-
Share Buybacks Continue
Cronos repurchased 12.3 million shares in H1 2026 under its $50M buyback program, reducing the share count to 370.7M as of June 30, 2026.
-
New Israeli Anti-Dumping Investigation
On August 5, 2026, Israel initiated a new anti-dumping investigation into Canadian medical cannabis imports. If duties are imposed, Cronos's Israeli sales — its fastest-growing segment — could be materially impacted.
Analysis · CRON · Life Sciences
Cronos delivered its strongest quarter yet — net revenue jumped 58% to $53 million, gross profit nearly doubled, and the company swung from a $38.5 million loss to a $35.7 million profit. Adjusted EBITDA hit $13.1 million, up from just $1.7 million a year ago. The results were driven by surging demand in Israel and Germany, where products carry no excise taxes, and by market share gains in Canada. The company also bought back 12.3 million shares in the first half of the year, returning capital to shareholders. However, a new anti-dumping investigation in Israel — launched just yesterday — threatens Cronos's most important growth market. If duties are imposed, the company's ability to sell profitably in Israel could be severely disrupted. The pending acquisition of CanAdelaar in the Netherlands adds another growth lever, but regulatory approval is still pending.
At the time of this filing, CRON was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.00 to $3.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.